Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Biogen Inc. (BIIB) Stock Moves -1.94%: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed at $283.44 in the latest trading session, marking a -1.94% move from the prior day.
Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines
by Zacks Equity Research
Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session.
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
by Zacks Equity Research
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
BIIB vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
BIIB vs. TECH: Which Stock Is the Better Value Option?
Novartis' (NVS) PNH Candidate Achieves Study Objectives
by Zacks Equity Research
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?
by Zacks Equity Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion (ESPR) Reports Positive Data From CLEAR Study
by Zacks Equity Research
Esperion (ESPR) announces positive data from the CLEAR Outcomes study, which further strengthens the clinical evidence supporting the role of bempedoic acid for patients and will boost the growth potential of the drug.
Is Biogen (BIIB) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage
by Zacks Equity Research
ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression
by Zacks Equity Research
Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
by Zacks Equity Research
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal
by Zacks Equity Research
Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal
by Kinjel Shah
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug
by Zacks Equity Research
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.
Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects
by Zacks Equity Research
Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage.
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion
by Zacks Equity Research
Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.
Biogen (BIIB) Down on Report of Death in Alzheimer's Study
by Zacks Equity Research
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
by Zacks Equity Research
CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
Gilead (GILD), RCUS Announce Positive Data From NSCLC Study
by Zacks Equity Research
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
by Zacks Equity Research
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.